

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC PHARMACEUTICAL
PRICING ANTITRUST LITIGATION

MDL NO. 2724
16-MD-2724
HON. CYNTHIA M. RUFÉ

THIS DOCUMENT RELATES TO:

ALL ACTIONS

PRETRIAL ORDER NO. 23
(SCHEDULING)

AND NOW, this 22nd day of May 2017, upon consideration of the pending motions, and after the Status Conference of May 4, 2017, and a telephone conference with Lead and Liaison Counsel held this date, it is hereby **ORDERED** that:


1. All amended proposed class action complaints shall be filed no later than **August 15, 2017**.
2. All discovery is stayed until **September 15, 2017**, with a further stay possible.
3. The attached stipulation between Plaintiffs and the United States, as intervenor, is **APPROVED**.

4. In light of the present stay, the Motions to Stay Discovery (MDL Doc. Nos. 202 and 279, Doc. No. 24 in Civil Action No. 16-6639, Doc. No. 22 in Civil Action No. 16-6644, and Doc. No. 23 in Civil Action No. 16-6662) are **DISMISSED WITHOUT PREJUDICE**.

5. Lead and Liaison Counsel shall meet and confer and file a report no later than **June 20, 2017**, on the status of proposed pretrial orders as to the preservation and protection of documents, including ESI.

It is so **ORDERED**.

BY THE COURT:


CYNTHIA M. RUFÉ, J.

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION	MDL 2724 16-MD-2724
THIS DOCUMENT RELATES TO: <i>ALL ACTIONS</i>	HON. CYNTHIA M. RUFE

**JOINT STIPULATION REGARDING
INTERVENOR UNITED STATES' MOTION TO STAY DISCOVERY**

WHEREAS, on May 1, 2017, Intervenor United States of America (the "United States") filed its Motion to Stay Discovery (ECF 279) seeking an Order staying discovery until 30 days after consolidated amended complaints concerning all drugs have been filed by all Plaintiff groups (the "Motion");

WHEREAS, Direct-Purchaser Plaintiffs ("DPPs"), End-Payer Plaintiffs ("EPPs"), and Indirect-Reseller Plaintiffs ("IRPs") (together, "Plaintiffs") do not oppose the relief sought by the Motion;

WHEREAS, counsel for the United States and counsel for DPPs and EPPs have met and conferred and all Plaintiffs, through the undersigned counsel, now stipulate as follows:

1. To promote efficient case management, and consistent with Defendants' proposed procedure as stated in Section III.A of their April 28, 2017 Status Report (ECF 271), all Plaintiffs intend to file their consolidated class action complaints for all generic pharmaceuticals presently part of MDL 2724 on or about August 15, 2017, subject to Court approval;

2. As of this date and continuing through the later of either September 15, 2017 or 30 days after the filing of the last of such consolidated class action complaints:

- a. Plaintiffs will not pursue discovery of Defendants; and
 - b. Plaintiffs and the United States will meet and confer about the timing and sequencing of appropriate document discovery directed to both parties and third parties; and
3. Plaintiffs will report to the Court on the status or outcome of their discussions with the United States during or immediately following the 30-day period after the filing of the last of the consolidated class action complaints;
4. Plaintiffs acknowledge that, depending on the results of the meet and confer between Plaintiffs and the United States, the United States reserves the right to refile its motion to stay discovery following the 30-day period after the filing of the last of the consolidated class action complaints;
5. Plaintiffs agree to provide notice and copies of all discovery requests to counsel for the United States contemporaneous with service on Defendants and third parties; and
6. In light of this Stipulation, Intervenor United States of America agrees that its Motion to Stay Discovery (ECF 279) may be denied without prejudice as moot.

IT IS SO STIPULATED.

Dated: May 15, 2017

/s/ Dianne M. Nast

Dianne M. Nast
NASTLAW LLC
1100 Market Street, Suite 2801
Philadelphia, PA 19107
215-923-9300
dnast@nastlaw.com

**Lead Counsel for Direct Purchaser
Plaintiffs**

/s/ Roberta D. Liebenberg

Roberta D. Liebenberg
FINE, KAPLAN AND BLACK, R.P.C.
One South Broad Street, 23rd Floor
Philadelphia, PA 19107
215-567-6565
rliebenberg@finekaplan.com

Lead Counsel for End-Payer Plaintiffs

/s/ Andrew J. Ewalt

Andrew J. Ewalt
Jay D. Owen
U.S. Department of Justice, Antitrust Division
450 Fifth St NW, Room 4120
Washington, DC 20530
Tel: (202) 532-4181
Fax: (202) 514-7308
andrew.ewalt@usdoj.gov


**Counsel for Intervenor United States of
America**

/s/ Jonathan W. Cuneo

Jonathan W. Cuneo
CUNEO GILBERT & LADUCA LLP
4725 Wisconsin Avenue, NW
Suite 200
Washington, DC 20016
202-789-3960
jonc@cuneolaw.com

**PSC Representative for Indirect-Reseller
Plaintiffs**

**Approved and so Ordered:
this ___ day of May, 2017**



CYNTHIA M. RUFÉ, J.